Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Transformation to Hodgkin Lymphoma in Chemotherapy-Naïve Patients with Chronic Lymphocytic Leukemia

  • By

  • Paul J. Hampel

  • Ying Huang

  • John N. Allan

  • Seema A. Bhat

  • David Bond

  • Danielle M. Brander

  • John C. Byrd

  • Julio C. Chavez

  • Elise Chong

  • Alexey Danilov

  • Matthew S. Davids

  • Kaitlyn Dvorak-Kornaus

  • Hannah Freedman

  • Nikita Malakhov

  • Matthew Matasar

  • Cecelia Miller

  • Sarah Miller

  • Zulfa Omer

  • Sameer A. Parikh

  • Erin M. Parry

  • Kari G. Rabe

  • Phil Raess

  • Manoj Rai

  • Joanna M. Rhodes

  • Kerry A. Rogers

  • Aditi Saha

  • Jake Schade

  • Geoffrey Shouse

  • Stephen Spurgeon

  • Deborah Stephens

  • Yucai Wang

  • Jennifer A. Woyach

  • Max Yano

  • Adam S. Kittai

  • September 26, 2026

Share

Clinical Scorecard: Transformation to Hodgkin Lymphoma in Chemotherapy-Naïve Patients with Chronic Lymphocytic Leukemia

At a Glance

CategoryDetail
ConditionHodgkin Lymphoma Transformation
Key MechanismsEmergence of aggressive lymphoma in CLL, primarily Hodgkin lymphoma in this context.
Target PopulationPatients with chronic lymphocytic leukemia (CLL) who develop Hodgkin lymphoma transformation.
Care SettingAcademic centers specializing in hematology and oncology.

Key Highlights

  • Hodgkin lymphoma transformation occurs in 1 of every 200 CLL patients within 10 years.
  • Patients with Hodgkin lymphoma transformation have longer survival compared to those with DLBCL transformation.
  • Median age at CLL diagnosis was 63 years; median age at HT diagnosis was 66 years.
  • Overall response rate to first-line HT treatment was 79%, with a 67% complete response rate.
  • 24-month overall survival was 80% across the cohort.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of Hodgkin lymphoma transformation should be confirmed through pathology.

Management

  • Initial management may include ABVD or brentuximab vedotin-based regimens.

Monitoring & Follow-up

  • Monitor response to treatment using Lugano 2014 criteria.

Risks

  • Prognostic factors for worse overall survival include TP53 disruption and elevated LDH levels.

Patient & Prescribing Data

Patients with CLL who have not received prior chemotherapy.

Treatment may involve small molecule inhibitors prior to HT diagnosis.

Clinical Best Practices

  • Consider the impact of prior CLL-directed therapy on disease biology and immune function.
  • Evaluate prognostic factors at HT diagnosis to inform treatment decisions.

Related Resources & Content

Original Source(s)

Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia

  • by Paul J. Hampel, Ying Huang, John N. Allan, Seema A. Bhat, David Bond, Danielle M. Brander, John C. Byrd, Julio C. Chavez, Elise Chong, Alexey Danilov, Matthew S. Davids, Kaitlyn Dvorak-Kornaus, Hannah Freedman, Nikita Malakhov, Matthew Matasar, Cecelia Miller, Sarah Miller, Zulfa Omer, Sameer A. Parikh, Erin M. Parry, Kari G. Rabe, Phil Raess, Manoj Rai, Joanna M. Rhodes, Kerry A. Rogers, Aditi Saha, Jake Schade, Geoffrey Shouse, Stephen Spurgeon, Deborah Stephens, Yucai Wang, Jennifer A. Woyach, Max Yano, Adam S. Kittai

  • September 26, 2026

Related Content

Roving Reporter Asks: How Is Cell and Gene Therapy Manufacturing Becoming More Scalable?

IBTV speaks with industry leaders at ASGCT 2026 about the technologies, processes, and manufacturing strategies helping advanced therapies progress toward commercial scale

  • September 18, 2026

  • 2 min
Posterior fossa ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes (Part I of ependymomas across compartments)

Safety-Oriented Benchmarking of Large Language Models in Risk-Based Management of Abnormal Cervical Screening Results: Scenario-Based Benchmark Study